Bolt Biotherapeutics, Inc.
BOLT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $408,568 | $846,988 | $971,319 | $3,665,170 |
| - Cash | $7,205 | $10,810 | $9,244 | $27,383 |
| + Debt | $25,209 | $20,219 | $22,611 | $24,355 |
| Enterprise Value | $426,572 | $856,397 | $984,686 | $3,662,142 |
| Revenue | $7,690 | $7,876 | $5,729 | $1,260 |
| % Growth | -2.4% | 37.5% | 354.7% | – |
| Gross Profit | $7,690 | -$53,666 | -$67,394 | -$74,395 |
| % Margin | 100% | -681.4% | -1,176.4% | -5,904.4% |
| EBITDA | -$66,455 | -$74,342 | -$88,655 | -$91,595 |
| % Margin | -864.2% | -943.9% | -1,547.5% | -7,269.4% |
| Net Income | -$63,118 | -$69,197 | -$88,098 | -$98,591 |
| % Margin | -820.8% | -878.6% | -1,537.8% | -7,824.7% |
| EPS Diluted | -1.65 | -1.83 | -2.3 | -2.79 |
| % Growth | 9.8% | 20.4% | 17.6% | – |
| Operating Cash Flow | -$61,289 | -$69,525 | -$76,504 | -$57,066 |
| Capital Expenditures | -$41 | -$206 | -$1,953 | -$2,338 |
| Free Cash Flow | -$61,330 | -$69,731 | -$78,457 | -$59,404 |